Lactic acid bacteria with concomitant IL-17, IL-23 and TNFα-binding ability for the treatment of inflammatory bowel disease

Current Pharmaceutical Biotechnology

Volumn 18, Issue 4, 2017, Pages 318-326

  Kosler, Staša ^a   Štrukelj, Borut ^a,b   Berlec, Aleš ^a  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

IL 17A; IL 23; Inflammatory bowel disease; Probiotics; Recombinant; TNF

Indexed keywords

HYBRID PROTEIN; INTERLEUKIN 17; INTERLEUKIN 23; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR; IL17A PROTEIN, HUMAN; PROBIOTIC AGENT; PROTEIN BINDING; TNF PROTEIN, HUMAN;

ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATORY BOWEL DISEASE; LACTIC ACID BACTERIUM; LACTOBACILLUS SALIVARIUS; MOLECULAR CLONING; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; RECEPTOR BINDING ASSAY; STOMACH JUICE; ANTAGONISTS AND INHIBITORS; GENETICS; HUMAN; LACTOCOCCUS LACTIS; METABOLISM; ORAL DRUG ADMINISTRATION; TRANSGENIC ORGANISM;

ADMINISTRATION, ORAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-17; INTERLEUKIN-23; LACTOCOCCUS LACTIS; ORGANISMS, GENETICALLY MODIFIED; PROBIOTICS; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85020391777     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201018666170210152218     Document Type: Article

References (40)

1. Baumgart, D.C.; Sandborn, W.J. Crohn’s disease. Lancet, 2012, 380(9853), 1590-1605.
2. Danese, S.; Fiocchi, C. Ulcerative colitis. N. Engl. J. Med., 2011, 365(18), 1713-1725.
3. Fitzpatrick, L.R. Novel pharmacological approaches for inflammatory bowel disease: Targeting key intracellular pathways and the IL-23/IL-17 axis. Int. J. Inflam., 2012, 2012, 389404.
4. Neurath, M.F. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol., 2014, 14(5), 329-342.
5. Xu, X.R.; Liu, C.Q.; Feng, B.S.; Liu, Z.J. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J. Gastroenterol., 2014, 20(12), 3255-3264.
6. Zabana, Y.; Domenech, E.; Manosa, M.; Garcia-Planella, E.; Bernal, I.; Cabre, E.; Gassull, M.A. Infliximab safety profile and longterm applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment. Pharmacol. Ther., 2010, 31(5), 553-560.
7. Catana, C.S.; Berindan Neagoe, I.; Cozma, V.; Magdas, C.; Tabaran, F.; Dumitrascu, D.L. Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J. Gastroenterol., 2015, 21(19), 5823-5830.
8. Fitzpatrick, L.R. Inhibition of IL-17 as a pharmacological approach for IBD. Int. Rev. Immunol., 2013, 32(5-6), 544-555.
9. Hueber, W.; Sands, B.E.; Lewitzky, S.; Vandemeulebroecke, M.; Reinisch, W.; Higgins, P.D.; Wehkamp, J.; Feagan, B.G.; Yao, M.D.; Karczewski, M.; Karczewski, J.; Pezous, N.; Bek, S.; Bruin, G.; Mellgard, B.; Berger, C.; Londei, M.; Bertolino, A.P.; Tougas, G.; Travis, S.P. Secukinumab in Crohn’s Disease Study, G., Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut, 2012, 61(12), 1693-1700.
10. McLean, M.H.; Neurath, M.F.; Durum, S.K. Targeting interleukins for the treatment of inflammatory bowel disease-what lies beyond anti-TNF therapy? Inflamm. Bowel Dis., 2014, 20(2), 389-397.
11. Manichanh, C.; Borruel, N.; Casellas, F.; Guarner, F. The gut microbiota in IBD. Nat. Rev. Gastroenterol. Hepatol., 2012, 9, (10), 599-608.
12. Ghouri, Y.A.; Richards, D.M.; Rahimi, E.F.; Krill, J.T.; Jelinek, K.A.; DuPont, A.W. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin. Exp. Gastroenterol., 2014, 7, 473-487.
13. deMoreno de LeBlanc, A.; Del Carmen, S.; Chatel, J.M.; Miyoshi, A.; Azevedo, V.; Langella, P.; Bermudez-Humaran, L.G.; LeBlanc, J.G. Current review of genetically modified lactic acid bacteria for the prevention and treatment of colitis using murine models. Gastroenterol. Res. Pract., 2015, 2015, 146972.
14. Berlec, A.; Ravnikar, M.; Strukelj, B. Lactic acid bacteria as oral delivery systems for biomolecules. Die Pharmazie, 2012, 67(11), 891-898.
15. Steidler, L.; Hans, W.; Schotte, L.; Neirynck, S.; Obermeier, F.; Falk, W.; Fiers, W.; Remaut, E., Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science, 2000, 289, (5483), 1352-1355.
16. Hanson, M.L.; Hixon, J.A.; Li, W.; Felber, B.K.; Anver, M.R.; Stewart, C.A.; Janelsins, B.M.; Datta, S.K.; Shen, W.; McLean, M.H.; Durum, S.K. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology, 2014, 146(1), 210-221 e213.
17. Motta, J.P.; Bermudez-Humaran, L.G.; Deraison, C.; Martin, L.; Rolland, C.; Rousset, P.; Boue, J.; Dietrich, G.; Chapman, K.; Kharrat, P.; Vinel, J.P.; Alric, L.; Mas, E.; Sallenave, J.M.; Langella, P.; Vergnolle, N. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci. Transl. Med., 2012, 4(158), 158ra144.
18. Quevrain, E.; Maubert, M.A.; Michon, C.; Chain, F.; Marquant, R.; Tailhades, J.; Miquel, S.; Carlier, L.; Bermudez-Humaran, L.G.; Pigneur, B.; Lequin, O.; Kharrat, P.; Thomas, G.; Rainteau, D.; Aubry, C.; Breyner, N.; Afonso, C.; Lavielle, S.; Grill, J.P.; Chassaing, G.; Chatel, J.M.; Trugnan, G.; Xavier, R.; Langella, P.; Sokol, H.; Seksik, P., Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease. Gut, 2015.
19. Ravnikar, M.; Strukelj, B.; Obermajer, N.; Lunder, M.; Berlec, A. Engineered lactic acid bacterium Lactococcus lactis capable of binding antibodies and tumor necrosis factor alpha. Appl. Environ. Microbiol., 2010, 76(20), 6928-6932.
20. Vandenbroucke, K.; de Haard, H.; Beirnaert, E.; Dreier, T.; Lauwereys, M.; Huyck, L.; Van Huysse, J.; Demetter, P.; Steidler, L.; Remaut, E.; Cuvelier, C.; Rottiers, P. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol., 2010, 3(1), 49-56.
21. Dieye, Y.; Usai, S.; Clier, F.; Gruss, A.; Piard, J.C. Design of a protein-targeting system for lactic acid bacteria. J. Bacteriol., 2001, 183(14), 4157-4166.
22. Zadravec, P.; Mavric, A.; Bogovic Matijasic, B.; Strukelj, B.; Berlec, A. Engineering BmpA as a carrier for surface display of IgGbinding domain on Lactococcus lactis. Prot. Eng. Des. Sel., 2014, 27(1), 21-27.
23. Okano, K.; Zhang, Q.; Kimura, S.; Narita, J.; Tanaka, T.; Fukuda, H.; Kondo, A. System using tandem repeats of the cA peptidoglycan-binding domain from Lactococcus lactis for display of both Nand C-terminal fusions on cell surfaces of lactic acid bacteria. Appl. Environ. Microbiol., 2008, 74(4), 1117-1123.
24. Hu, S.; Kong, J.; Sun, Z.; Han, L.; Kong, W.; Yang, P. Heterologous protein display on the cell surface of lactic acid bacteria mediated by the s-layer protein. Microb. Cell Fact., 2011, 10, 86.
25. Horii, K.; Adachi, T.; Tanino, T.; Tanaka, T.; Sahara, H.; Shibasaki, S.; Ogino, C.; Hata, Y.; Ueda, M.; Kondo, A. Evaluation of cell surface-displayed protein stability against simulated gastric fluid. Biotechnol. Lett., 2009, 31(8), 1259-1264.
26. Zadravec, P.; Strukelj, B.; Berlec, A. Heterologous surface display on lactic acid bacteria: Non-GMO alternative? Bioengineered, 2015, 6(3), 179-183.
27. Zadravec, P.; Strukelj, B.; Berlec, A. Improvement of LysMmediated surface display of designed ankyrin repeat proteins (DARPins) in recombinant and nonrecombinant strains of Lactococcus lactis and Lactobacillus Species. Appl. Environ. Microbiol., 2015, 81(6), 2098-2106.
28. Steen, A.; Buist, G.; Leenhouts, K.J.; El Khattabi, M.; Grijpstra, F.; Zomer, A.L.; Venema, G.; Kuipers, O.P.; Kok, J. Cell wall attachment of a widely distributed peptidoglycan binding domain is hindered by cell wall constituents. J. Biol. Chem., 2003, 278(26), 23874-23881.
29. Skrlec, K.; Strukelj, B.; Berlec, A. Non-immunoglobulin scaffolds: a focus on their targets. Trends Biotechnol., 2015, 33(7), 408-418.
30. Silacci, M.; Baenziger-Tobler, N.; Lembke, W.; Zha, W.; Batey, S.; Bertschinger, J.; Grabulovski, D. Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency. J. Biol. Chem., 2014, 289(20), 14392-14398.
31. Ramamurthy, V.; Krystek, S.R., Jr.; Bush, A.; Wei, A.; Emanuel, S.L.; Das Gupta, R.; Janjua, A.; Cheng, L.; Murdock, M.; Abramczyk, B.; Cohen, D.; Lin, Z.; Morin, P.; Davis, J.H.; Dabritz, M.; McLaughlin, D.C.; Russo, K.A.; Chao, G.; Wright, M.C.; Jenny, V.A.; Engle, L.J.; Furfine, E.; Sheriff, S. Structures of adnectin/ protein complexes reveal an expanded binding footprint. Structure, 2012, 20(2), 259-269.
32. Jonsson, A.; Wallberg, H.; Herne, N.; Stahl, S.; Frejd, F.Y. Generation of tumour-necrosis-factor-alpha-specific affibody molecules capable of blocking receptor binding in vitro. Biotechnol. Appl. Biochem., 2009, 54(2), 93-103.
33. Holo, H.; Nes, I.F. Transformation of Lactococcus by electroporation. Methods Mol. Biol., 1995, 47, 195-199.
34. Charteris, W.P.; Kelly, P.M.; Morelli, L.; Collins, J.K. Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract. J. Appl. Microbiol., 1998, 84(5), 759-768.
35. Mierau, I.; Kleerebezem, M. 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl. Microbiol. Biotechnol., 2005, 68(6), 705-717.
36. Berlec, A.; Malovrh, T.; Zadravec, P.; Steyer, A.; Ravnikar, M.; Sabotič, J.; Poljšak-Prijatelj, M.; Štrukelj, B. Expression of a hepatitis A virus antigen in Lactococcus lactis and Escherichia coli and evaluation of its immunogenicity. Appl. Microbiol. Biotechnol., 2013, 97(10), 4333-4342.
37. Messaoudi, S.; Manai, M.; Kergourlay, G.; Prevost, H.; Connil, N.; Chobert, J.M.; Dousset, X. Lactobacillus salivarius: Bacteriocin and probiotic activity. Food Microbiol., 2013, 36(2), 296-304.
38. Macho Fernandez, E.; Valenti, V.; Rockel, C.; Hermann, C.; Pot, B.; Boneca, I.G.; Grangette, C. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut, 2011, 60(8), 1050-1059.
39. McCarthy, J.; O’Mahony, L.; O’Callaghan, L.; Sheil, B.; Vaughan, E.E.; Fitzsimons, N.; Fitzgibbon, J.; O’Sullivan, G.C.; Kiely, B.; Collins, J.K.; Shanahan, F. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut, 2003, 52(7), 975-980.
40. Chen, R.; Chen, Q.; Kim, H.; Siu, K.H.; Sun, Q.; Tsai, S.L.; Chen, W. Biomolecular scaffolds for enhanced signaling and catalytic efficiency. Curr. Opin. Biotechnol., 2014, 28, 59-68.